FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891912276> ?p ?o ?g. }

• W2891912276 endingPage "6195" @default.
• W2891912276 startingPage "6183" @default.
• W2891912276 abstract "Abstract Cancer immunotherapies that remove checkpoint restraints on adaptive immunity are gaining clinical momentum but have not achieved widespread success in breast cancers, a tumor type considered poorly immunogenic and which harbors a decreased presence of tumor-infiltrating lymphocytes. Approaches that activate innate immunity in breast cancer cells and the tumor microenvironment are of increasing interest, based on their ability to induce immunogenic tumor cell death, type I IFNs, and lymphocyte-recruiting chemokines. In agreement with reports in other cancers, we observe loss, downregulation, or mutation of the innate viral nucleotide sensor retinoic acid-inducible gene I (RIG-I/DDX58) in only 1% of clinical breast cancers, suggesting potentially widespread applicability for therapeutic RIG-I agonists that activate innate immunity. This was tested using an engineered RIG-I agonist in a breast cancer cell panel representing each of three major clinical breast cancer subtypes. Treatment with RIG-I agonist resulted in upregulation and mitochondrial localization of RIG-I and activation of proinflammatory transcription factors STAT1 and NF-κB. RIG-I agonist triggered the extrinsic apoptosis pathway and pyroptosis, a highly immunogenic form of cell death in breast cancer cells. RIG-I agonist also induced expression of lymphocyte-recruiting chemokines and type I IFN, confirming that cell death and cytokine modulation occur in a tumor cell–intrinsic manner. Importantly, RIG-I activation in breast tumors increased tumor lymphocytes and decreased tumor growth and metastasis. Overall, these findings demonstrate successful therapeutic delivery of a synthetic RIG-I agonist to induce tumor cell killing and to modulate the tumor microenvironment in vivo. Significance: These findings describe the first in vivo delivery of RIG-I mimetics to tumors, demonstrating a potent immunogenic and therapeutic effect in the context of otherwise poorly immunogenic breast cancers. Cancer Res; 78(21); 6183–95. ©2018 AACR." @default.
• W2891912276 created "2018-09-27" @default.
• W2891912276 creator A5005134586 @default.
• W2891912276 creator A5007909912 @default.
• W2891912276 creator A5031507912 @default.
• W2891912276 creator A5037252693 @default.
• W2891912276 creator A5037945408 @default.
• W2891912276 creator A5037982412 @default.
• W2891912276 creator A5039149479 @default.
• W2891912276 creator A5041028923 @default.
• W2891912276 creator A5074339344 @default.
• W2891912276 creator A5088010294 @default.
• W2891912276 date "2018-11-01" @default.
• W2891912276 modified "2023-10-17" @default.
• W2891912276 title "Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers" @default.
• W2891912276 cites W1513841153 @default.
• W2891912276 cites W1544887050 @default.
• W2891912276 cites W1572267688 @default.
• W2891912276 cites W1621339884 @default.
• W2891912276 cites W1895814318 @default.
• W2891912276 cites W1908864745 @default.
• W2891912276 cites W1968178474 @default.
• W2891912276 cites W1972141585 @default.
• W2891912276 cites W2005895632 @default.
• W2891912276 cites W2017515700 @default.
• W2891912276 cites W2032948492 @default.
• W2891912276 cites W2041888585 @default.
• W2891912276 cites W2042433863 @default.
• W2891912276 cites W2060004514 @default.
• W2891912276 cites W2066671159 @default.
• W2891912276 cites W2094499147 @default.
• W2891912276 cites W2097200850 @default.
• W2891912276 cites W2097995306 @default.
• W2891912276 cites W2107513655 @default.
• W2891912276 cites W2120921261 @default.
• W2891912276 cites W2148482462 @default.
• W2891912276 cites W2156869719 @default.
• W2891912276 cites W2159829473 @default.
• W2891912276 cites W2171745628 @default.
• W2891912276 cites W2173816666 @default.
• W2891912276 cites W2220279767 @default.
• W2891912276 cites W2227155638 @default.
• W2891912276 cites W2237126693 @default.
• W2891912276 cites W2296705508 @default.
• W2891912276 cites W2329718078 @default.
• W2891912276 cites W2345415641 @default.
• W2891912276 cites W2504940557 @default.
• W2891912276 cites W2562493667 @default.
• W2891912276 cites W2589103622 @default.
• W2891912276 cites W2597669462 @default.
• W2891912276 cites W2625922832 @default.
• W2891912276 cites W2735060541 @default.
• W2891912276 cites W2748586815 @default.
• W2891912276 cites W2769016931 @default.
• W2891912276 cites W2769142715 @default.
• W2891912276 cites W2783421775 @default.
• W2891912276 cites W2788640168 @default.
• W2891912276 cites W2794063791 @default.
• W2891912276 cites W2915478882 @default.
• W2891912276 cites W4243831105 @default.
• W2891912276 doi "https://doi.org/10.1158/0008-5472.can-18-0730" @default.
• W2891912276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30224377" @default.
• W2891912276 hasPublicationYear "2018" @default.
• W2891912276 type Work @default.
• W2891912276 sameAs 2891912276 @default.
• W2891912276 citedByCount "121" @default.
• W2891912276 countsByYear W28919122762018 @default.
• W2891912276 countsByYear W28919122762019 @default.
• W2891912276 countsByYear W28919122762020 @default.
• W2891912276 countsByYear W28919122762021 @default.
• W2891912276 countsByYear W28919122762022 @default.
• W2891912276 countsByYear W28919122762023 @default.
• W2891912276 crossrefType "journal-article" @default.
• W2891912276 hasAuthorship W2891912276A5005134586 @default.
• W2891912276 hasAuthorship W2891912276A5007909912 @default.
• W2891912276 hasAuthorship W2891912276A5031507912 @default.
• W2891912276 hasAuthorship W2891912276A5037252693 @default.
• W2891912276 hasAuthorship W2891912276A5037945408 @default.
• W2891912276 hasAuthorship W2891912276A5037982412 @default.
• W2891912276 hasAuthorship W2891912276A5039149479 @default.
• W2891912276 hasAuthorship W2891912276A5041028923 @default.
• W2891912276 hasAuthorship W2891912276A5074339344 @default.
• W2891912276 hasAuthorship W2891912276A5088010294 @default.
• W2891912276 hasConcept C121608353 @default.
• W2891912276 hasConcept C13373296 @default.
• W2891912276 hasConcept C136449434 @default.
• W2891912276 hasConcept C170493617 @default.
• W2891912276 hasConcept C203014093 @default.
• W2891912276 hasConcept C2776107976 @default.
• W2891912276 hasConcept C2778938600 @default.
• W2891912276 hasConcept C2779013556 @default.
• W2891912276 hasConcept C502942594 @default.
• W2891912276 hasConcept C530470458 @default.
• W2891912276 hasConcept C54355233 @default.
• W2891912276 hasConcept C55493867 @default.
• W2891912276 hasConcept C86803240 @default.
• W2891912276 hasConcept C8891405 @default.
• W2891912276 hasConceptScore W2891912276C121608353 @default.

• next